The Confirming Quarter Arrives: Aesthetics Troughs, the Engines Re-Accelerate, and the Tape Finally Rewards the Beat — Upgrading to Outperform After Three Disciplined Holds.

Results vs. Consensus

Q1 2026 Scorecard

Year-Over-Year Comparison (Q1)

The shape of the YoY table is the whole story of the upgrade. Three of four franchises grew, two of them in double digits, and the fourth — aesthetics — flipped from a year of declines to +7.6%. Only oncology was modestly down (−0.2% reported), and that is a single, well-understood line (Imbruvica IRA pricing). Compare this to Q4’s table, where two franchises were declining (oncology and aesthetics): the laggard count just halved. The adjusted-EPS line (+7.7%) understates the operational strength because it still carries the $0.41 IPR&D charge; the ex-IPR&D ~$3.06 grew faster.

Sequential (QoQ) Context

The sequential declines are seasonal, not deteriorating. Q1 is structurally AbbVie’s lowest revenue quarter every year — U.S. immunology gross-to-net resets in January (the deductible/coverage-gap dynamic that front-loads rebates into Q1), and aesthetics steps down from the holiday-heavy Q4. Management’s own Q2 guide of ~$16.7B (a ~+11% sequential rebound) confirms the Q1 dip is the annual trough, not a trend. The number to anchor on is the YoY (+12.4%), not the QoQ. Vyalev is the exception that proves the point: it grew ~10% sequentially to $201M even into the seasonal-low quarter.

Quality of Beat

Revenue: The ~$0.25B Q1 overachievement was concentrated exactly where the thesis wants it — Skyrizi (+29.2% op.) and Rinvoq (+20.2% op.) in immunology, and a broad neuroscience beat (+24.3% op.) — not in one-time items or channel stocking. Reported growth of 12.4% versus operational 10.3% means FX was a ~2.1pt favorable tailwind, but the operational figure itself accelerated off Q4. The off-scorecard number that confirms the engine: Skyrizi alone added ~$1B of immunology growth, and management raised the full-year Skyrizi guide a second time.

Margins: The reported adjusted operating margin of 40.8% carries a 5.0-point unfavorable hit from acquired IPR&D this quarter; strip it and the underlying margin is back in the mid-40s, consistent with AbbVie at scale. Adjusted gross margin of 83.6% was in line and reiterated above 84% for the full year. The mix continues to improve quietly: the two highest-margin franchises (immunology, neuroscience) are growing fastest, and aesthetics — now growing rather than shrinking — adds incremental contribution rather than subtracting it. The 2026 operating-margin guide of ~47.5% (ex the ~1% YTD IPR&D drag) embeds meaningful expansion.

EPS: The beat is fully operational. The $0.41 IPR&D charge and its tax treatment sit inside both the print and the consensus bar, so they net out of the beat/miss. The adjusted tax rate of 15.4% and net interest expense of $645M were as modeled (the latter guided down $100M for the year on favorable debt rates). The cleaner read is the ex-IPR&D ~$3.06, which management explicitly flagged as $0.07 above its own midpoint — the operational earnings power is running ahead of plan a quarter into the year, which is precisely what let management raise the full-year guide.

Segment Performance

Therapeutic-Area Revenue Mix — Q1 2026

Aesthetics — The Trough Is In: Return to Growth After a Year of Declines

We lead with aesthetics because it is the franchise that flips the thesis. After a 2025 of declines — roughly −8% early in the year, −6.1% for the full year — the portfolio grew 7.6% reported and 5.1% operationally to $1.186B, its first positive print in over a year. The composition is encouraging: Botox Cosmetic, the larger and structurally healthier toxin line, grew 17% to $668M (helped by a favorable U.S. price comparison plus modest global market growth), while Juvederm fell only 2.9% to $232M — a sharply narrower filler decline than the double-digit drops of 2025. Management framed the category as stabilizing off a multi-year inflationary consumer-pressure cycle rather than snapping back, but the numbers themselves crossed into positive territory.

“Moving now to aesthetics, which delivered global sales of nearly $1.2 billion, up 5.1% on an operational basis. Botox Cosmetic total revenues were $668 million, up 17%... While economic headwinds have continued to impact market conditions globally, the long-term prospects for the category remain attractive given high consumer interest and low penetration rates.” — Jeffrey Stewart, Chief Commercial Officer

The one negative footnote is regulatory, not commercial: the fast-acting short-duration toxin (the U.S. market-expansion catalyst management has touted) received a complete response letter tied to manufacturing questions — explicitly not safety, efficacy, or labeling, and with no new clinical trials requested — pushing the U.S. launch while international approvals (Europe, Canada, Japan) proceed this year.

Assessment: This is the single most important data point in the print for our rating, because the “confirmed aesthetics trough” was one of three explicit upgrade triggers we have carried since the Q2 initiation. At Q4 we wrote that aesthetics was “closer to a trough but not confirmed — one clean quarter from flipping positive.” This is that quarter. A market-leading, low-penetration, cash-pay category that has stopped shrinking and started growing again — even modestly — converts from a consolidated-growth-rate drag into a contributor, and removes the bear’s cleanest structural argument. Trigger confirmed.

Immunology — The Engine Re-Accelerates Through the Humira Tail

Immunology delivered Q1 revenues of $7.290B, up 16.4% reported and 14.3% operationally — an acceleration, with the composition again the story. Skyrizi grew 29.2% operationally to $4.483B and Rinvoq grew 20.2% operationally to $2.119B — a combined ~$6.6B still compounding ~25% — while Humira fell 40.3% operationally to just $688M, now a genuinely de-minimis tail (under 5% of total company revenue). Management detailed Skyrizi’s >4x in-play share lead over the next competitor in psoriatic disease, accelerating new-patient starts hitting all-time highs, IBD on track for >30% growth, and a strong subcutaneous-induction Crohn’s readout that supports first-line use. Rinvoq is achieving high-teens in-play share in room indications with a UC inflection following its expanded label.

“I’ll start with the quarterly results for immunology, which delivered total revenues of $7.3 billion reflecting impressive sales growth of $1 billion. Skyrizi total sales were $4.5 billion, up 29.2% on an operational basis, exceeding our expectations.” — Jeffrey Stewart, Chief Commercial Officer

Notably, Skyrizi net pricing was roughly flat in Q1 (slightly better than the low-single-digit erosion guided), which the CFO attributed to a year-over-year comparison gating issue, reiterating low-single-digit pricing for the full year. Underlying demand growth was ~30%, consistent with IQVIA scripts.

Assessment: This remains the load-bearing wall of the thesis, and it not only held but accelerated. The combined Skyrizi/Rinvoq raise — management lifted the Skyrizi full-year guide to ~$21.6B and Rinvoq to ~$10.2B (a combined >$31.8B) — keeps the franchise above its old 2027 long-term target, and the CEO repeatedly asserted upside to sell-side consensus “in every year, growing each year.” The only debate left on this franchise is the multiple, not the trajectory — and the multiple just got cheaper.

Neuroscience — The Second Engine Posts Its Strongest Growth Yet

Neuroscience grew 26.0% reported and 24.3% operationally to $2.875B — the fastest-growing therapeutic area and the strongest growth rate it has printed in our coverage. The drivers were broad: Vraylar at $905M (+18.4%, strong scripts in bipolar and adjunctive MDD), Botox Therapeutic at $1.009B (double-digit growth), and combined Ubrelvy + Qulipta at $635M in migraine. The standout for optionality remains Parkinson’s: Vyalev grew ~10% sequentially to $201M even into the seasonal-low quarter, and management reiterated it is “on track to achieve blockbuster revenue this year,” with the tavapadon oral launch positioned for H2 2026 to deepen the franchise.

“Moving to Parkinson’s disease, we continue to see encouraging uptake for VYALEV, which is on track to achieve blockbuster revenue this year. Total sales were $201 million, up approximately 10% on a sequential basis.” — Jeffrey Stewart, Chief Commercial Officer

Management again argued the Street under-weights neuroscience, sizing the Parkinson’s franchise (Vyalev + tavapadon + Duopa) at a peak above $5B and the migraine franchise above $5B — both above where it says consensus models peak (below $4B) — alongside a deep psychiatry pipeline (emraclidine, bretisilocin, 932) to replace Vraylar at its end-of-decade LOE.

Assessment: Neuroscience is now unambiguously a genuine, under-modeled second pillar, and Q1 raised the full-year neuroscience guide to ~$12.6B. The Vyalev/tavapadon Parkinson’s leg is the cleanest piece of un-modeled optionality in the portfolio, and a new growth driver ramping into a blockbuster mid-cycle is exactly what a de-rated compounder needs the market to start paying for. This quarter, for the first time, it did.

Oncology — Still the Lone Drag, but a Small and Well-Understood One

Oncology was the only franchise to decline, down 0.2% reported and 3.0% operationally to $1.631B — essentially flat reported, a marginal operational decline. The dynamic is unchanged and entirely explicable: Imbruvica fell 24.7% operationally to $556M on IRA pricing and competitive CLL share pressure, outweighing genuine strength elsewhere. Venclexta grew 9.7% operationally to $770M, with all-oral fixed-duration BTK-combination use building in CLL and recent full approvals in the U.S. and U.K., and Elahere contributed $198M. The R&D narrative again outpaces the revenue line: the Temab-A ADC is advancing across head-and-neck, ovarian, and an all-comers colorectal Phase III, and the new PD-1×VEGF bispecific will combine with it across solid tumors.

“Continued sales growth from [our newer assets] also helped to partially offset the expected sales decline for IMBRUVICA, which was down 24.7% due to IRA pricing and competitive share pressure.” — Jeffrey Stewart, Chief Commercial Officer

Assessment: Oncology is the residual risk we explicitly flag with the upgrade. But its character has changed: at Q4 it was one of two declining franchises and was guided down for the year; at Q1 it is the only declining franchise, the decline is marginal (−0.2% reported), and the cause is a single eroding asset (Imbruvica) whose absolute drag shrinks every quarter as its base falls. Against two double-digit engines plus a recovering aesthetics line, a small, well-understood, self-limiting oncology drag is not enough to keep the rating at Hold. It is a watch item, not a thesis-breaker — with the ADC/bispecific pipeline an option on the back half of the decade.

Key Topics & Management Commentary

Overall Management Tone: The most confident and forward-leaning posture of our coverage window — the CEO opened by calling it “an excellent start to the year” with results “exceeding our expectations across our diverse portfolio,” and the call spent most of its airtime on the durability of the Skyrizi/Rinvoq lead and the breadth of the neuroscience, oncology, and now obesity pipelines rather than defending any single soft spot. Where the Q4 call had to concede a flat aesthetics guide and a soft Q1 setup, this call had a clean beat-and-raise to deliver and a recovering aesthetics line to point to; management was least pressed on, and spent the least time defending, the one remaining drag (oncology/Imbruvica), which it treated as a fully-modeled known.

1. Aesthetics Returns to Growth — The Trough Confirmed

The single most thesis-relevant disclosure of the call was the simplest: aesthetics grew again. After management spent 2025 conceding a “more chronic” and “more lingering inflationary” consumer headwind, the franchise posted +5.1% operational growth, led by Botox Cosmetic +17%. Management was careful not to over-claim a full category recovery — characterizing the market as “relative stability now” with low-single-digit toxin growth and still-declining fillers — but the franchise crossed into positive territory.

“I think we’re seeing relative stability in the markets now. I mean, low single-digit growth for toxins, still decline for fillers. I do think it’s a different cycle of pressure on the consumer.” — Jeffrey Stewart, Chief Commercial Officer

Assessment: Honesty about the category cuts both ways — management is not declaring victory, which makes the +5.1% print more credible, not less. For our purposes the bar was never “category boom”; it was “has the franchise stopped subtracting from the consolidated growth rate.” It has. Trigger confirmed.

2. The Skyrizi/Rinvoq Trajectory — Raised Again, Upside to Consensus Reasserted

Management raised the full-year Skyrizi guide (+$100M to ~$21.6B) and Rinvoq guide (+$100M to ~$10.2B), and the CEO reasserted — repeatedly and unprompted — that AbbVie sees upside to sell-side consensus on both products in every year, with the gap growing each year. Pressed on whether that triangulates with discontinuing formal mid-term product guidance, the CEO held firm that the company is in its strongest-ever position and would not rule out reissuing long-term guidance later.

“We continue to see upside to consensus forecast for Skyrizi going out every year and growing each year. And so we have a tremendous amount of confidence. We are well aware of the competition that’s coming in. We factored that in, and you can see the asset continues to perform exceptionally well.” — Robert Michael, Chairman & CEO

Assessment: The second upgrade trigger — the long-term franchise raise — arrived inside the Q4 guide and was reaffirmed and incrementally lifted here. A management team that keeps guiding above the Street’s out-year peaks while raising the current year is the definition of the “under-promise” setup we want to own going into a multiple re-rate.

3. The Raised 2026 Guide and the IPR&D Basis

Management lifted the FY2026 adjusted-EPS guide by $0.12 to $14.08–$14.28 and revenue by ~$300M to ~$67.3B. The critical literacy point: this range now includes the $0.41 YTD IPR&D charge incurred through Q1, but excludes any IPR&D beyond Q1. At Q4 the guide ($14.37–$14.57) excluded IPR&D entirely. So the headline range optically fell — but that is purely the $0.41 charge now being inside the number.

“We are raising our full year adjusted earnings per share guidance to between $14.08 and $14.28. Please note that this guidance does not include an estimate for acquired IP R&D expense that may be incurred beyond the first quarter.” — Scott Reents, Chief Financial Officer

The arithmetic: netting the $0.41 back, the clean ex-IPR&D FY2026 guide is ~$14.49–$14.69 (mid ~$14.59), versus the Q4 ex-IPR&D guide of $14.37–$14.57 (mid ~$14.47). That is an operational raise of ~$0.12 at the midpoint — precisely the $0.12 the CEO said they were adding. The optical “lower” headline is a basis difference, not a guide cut.

Assessment: This is the recurring ABBV analytical signature, and getting it right is the difference between “AbbVie cut the guide” (wrong) and “AbbVie raised the operational guide $0.12 and folded the YTD BD bill into the headline” (right). At Q4 we said we wanted the first clean 2026 print to confirm the ~$14.47 ex-IPR&D number was durable earnings power and not partly accounting. It confirmed it — and then raised it. That confirmation is the third leg of the upgrade.

4. The Vyalev Ramp and the Neuroscience Pillar

Vyalev grew ~10% sequentially to $201M into the seasonal-low quarter and was reiterated as a 2026 blockbuster, with the tavapadon oral launch positioned for H2 to give AbbVie a Parkinson’s franchise the CEO sized at >$5B peak. Combined with migraine (>$5B) and psychiatry, the CEO claimed industry leadership in neuroscience “for a very long time.”

“[Vyalev plus tavapadon and Duopa give us] essentially a business of Parkinson’s that we expect to peak above $5 billion. That’s 1 of $5 billion-plus franchises between psychiatry, migraine and Parkinson’s that... can really drive AbbVie’s leadership in neuroscience.” — Robert Michael, Chairman & CEO

Assessment: A new asset ramping into blockbuster status mid-cycle, with a complementary oral launch six months out, is the kind of visible, near-term, un-modeled growth that a re-rating needs. The +26% neuroscience print made it impossible to ignore this quarter.

5. Oncology / IRA Pricing — The Known Drag

Imbruvica fell 24.7% operationally on IRA pricing and CLL competition, the lone franchise-level decline. Management treated it as fully modeled and offset by Venclexta strength (+9.7% op., now with fixed-duration BTK-combination approvals) and the emerging solid-tumor ADC pipeline. The oncology revenue line is a near-term drag; the pipeline is the multi-year option.

Assessment: The right way to hold this is as a small, self-limiting headwind — Imbruvica’s absolute dollar drag shrinks as its base erodes — not a structural threat. It is the residual risk to the Outperform call, but it is bounded and known.

6. Capital Allocation — Record Investment, Active BD, Growing Dividend

The CFO reiterated the three-pronged capital framework: investing in the business at record levels (including the $100B U.S. R&D/capex decade commitment, with new North Carolina and North Chicago manufacturing sites announced this quarter), pursuing business development from a position of financial strength, and returning capital through a “strong and growing dividend.” The CEO emphasized AbbVie does not need BD to deliver top-tier growth this decade but remains very active in neuroscience, oncology, and obesity.

“Our capital allocation priorities remain focused on the future as we are investing in the business at record levels, have financial flexibility to pursue compelling business development and returning capital to shareholders through our strong and growing dividend.” — Scott Reents, Chief Financial Officer

Assessment: The ~3.4% dividend yield at the de-rated price is a material part of the total-return case underpinning the upgrade. BD-from-strength (rather than BD-from-necessity ahead of an LOE, as in the Humira era) is the healthier posture and keeps the IPR&D charges a feature of optionality, not a tax on survival.

7. Pipeline Breadth — Obesity Optionality Emerges

The pipeline update was unusually broad, but the new strategic note was obesity: positive Phase I top-line data for the long-acting amylin analog ABBV-295 showed ~10% weight loss in 12 weeks in a predominantly male, non-obese population with mild, transient GI tolerability and no severe events. Management framed an obesity portfolio strategy around 295 — combinations, muscle-preservation assets, and aesthetics-channel go-to-market synergy.

“In obesity, positive top line results were announced from a multiple ascending dose study, evaluating our long-acting amylin analog, ABBV-295... 295 demonstrated clinically meaningful weight loss of nearly 10% after only 12 weeks of treatment.” — Roopal Thakkar, EVP, R&D

Assessment: Obesity is a genuine new optionality leg — early, but in the single largest pharma TAM of the decade, with a differentiated (amylin/once-monthly, muscle-sparing) angle and an aesthetics distribution synergy unique to AbbVie. Not in any model today; pure upside optionality.

8. The Immunology Combination Pipeline — Raising the Bar on Itself

Management detailed the next-generation immunology strategy: the Skyrizi + anti-α4β7 (ABBV-382) combination doubled endoscopic remission versus either monotherapy in a refractory Crohn’s interim, with a Phase IIb planned and acceleration options under discussion; the Skyrizi + lutikizumab arm was discontinued for insufficient differentiation. The strategic message: AbbVie intends to defend its I&I lead with its own combinations rather than cede it to single-mechanism competitors.

“What you see coming from AbbVie is next-generational therapies and really raising the bar on efficacy... we doubled the endoscopic data. And that’s really what’s most critical... we have not seen a competitor that can beat that other than us with our own combinations.” — Roopal Thakkar, EVP, R&D

Assessment: This directly addresses the bear’s most durable long-term worry — that the I&I franchise faces a wave of competition late this decade. Management’s answer is to out-innovate with internal combinations, and the doubling of endoscopic remission is a credible early data point. It pushes the competitive-erosion debate further out and supports the “upside to out-year consensus” claim.

Guidance & Outlook

*The $13.96–$14.16 figure is the prior guide as restated onto the IPR&D-inclusive basis the Q1 raise is struck on; the Q4 published guide of $14.37–$14.57 was on the ex-IPR&D basis. The two rows above show both bases explicitly so the “raise” is unambiguous on each.

The Q2 guide is the tell that the Q1 sequential dip is seasonal: management guided Q2 revenue to ~$16.7B (a ~+11% sequential rebound off Q1’s $15.002B) and Q2 adjusted EPS to $3.74–$3.78, with operating margin snapping back to ~50%. That implies the full year is comfortably back-half-weighted in the normal AbbVie pattern, not decelerating. The CFO reiterated FY gross margin above 84% and walked the net-interest line down $100M on favorable debt rates — a small but real below-the-line tailwind.

Implied full-year ramp: with Q1 at $2.65 (reported) / ~$3.06 (ex-IPR&D) and Q2 guided to $3.74–$3.78, the H1 run-rate sits comfortably inside the ~$14.08–$14.28 (reported) / ~$14.49–$14.69 (ex-IPR&D) full-year frame, leaving the guide achievable without a back-half heroics assumption. Street at: the reported-basis full-year consensus was sitting near the prior ~$14.06 midpoint; the raised guide pulls the Street up. Guidance style: consistent with AbbVie’s long-running pattern of guiding conservatively and raising through the year — the first raise of 2026 came one quarter in, on the back of a beat management itself sized at ~$300M above its own bar.

Analyst Q&A Highlights

Skyrizi’s Competitive Moat Against the Oral Wave

The dominant opening line of questioning was whether the rollout of competing oral agents threatens Skyrizi’s share trajectory. Management answered with unusual granularity — >4x in-play share over the next competitor, accelerating new-patient starts at all-time highs, head-to-head superiority data in five mechanisms, and the argument that competition is already embedded in the (twice-raised) Skyrizi guide.

Q: “I wanted to get your thoughts on the competitive landscape, particularly with the rollout of [the oral competitor]... give us some color on your counter-detailing messages to practitioners regarding the product as you enter this period with more intensive competition.”
— David Amsellem, Piper Sandler

A: “Despite incredibly high share, really over 4x basically the in-play share and total share versus the next leading competitor, our NBRx has accelerated and continued to hit all-time highs... it’s not an oral Skyrizi; the efficacy parameters are quite a bit lower when you match all the controls... We’re well prepared for this dynamic.”
— Jeffrey Stewart, Chief Commercial Officer

Assessment: Management did not deflect — it leaned in with data. The fact that new-patient starts are hitting all-time highs during the competitive entry is the strongest possible rebuttal to the share-erosion bear case, and it is why the franchise guide could be raised even with competition explicitly in view.

Defending the I&I Lead With Internal Combinations

A recurring concern was how AbbVie sustains its immunology position against a broad wave of competitor development. Management’s answer reframed the question: rather than defend with the existing monotherapies alone, it intends to raise the standard of care with its own next-generation combinations — citing the doubling of endoscopic remission with the Skyrizi + 382 combo.

Q: “The Street is increasingly concerned about [I&I competition] relative to your portfolio. So can you just kind of address... how you think about sustaining the competitive position you have in I&I, how important the Skyrizi combo is?”
— Christopher Schott, JPMorgan

A: “What you see coming from AbbVie is next-generational therapies and really raising the bar on efficacy... we doubled the endoscopic data... we have not seen a competitor that can beat that other than us with our own combinations, and we have more to come.”
— Roopal Thakkar, EVP, R&D

Assessment: This is the most important exchange for the out-year thesis. Management is not relying on Skyrizi/Rinvoq durability alone — it is building the next moat now. The combination data is early but directionally strong, and it pushes the competitive-cliff debate further out, supporting the “upside to out-year consensus” claim.

Skyrizi/Rinvoq Out-Year Consensus and the Mid-Term Guidance Gap

A pointed line of questioning probed how the CEO’s repeated “upside to consensus” claim squares with the decision to stop issuing formal mid-term product guidance, and where the largest disconnects to the Street remain.

Q: “In the context of the statements that you continue to see upside to consensus forecast for both Skyrizi and [Rinvoq] going out each year... how does that triangulate with your calculus of no longer updating mid-term guidance for these products? And... are there still areas where you see meaningful disconnect versus consensus outside of those 2 products?”
— Asad Haider, Goldman Sachs

A: “We do see upside. We see upside for the total company revenue in every year with that upside growing... in neuroscience we see upside versus expectations for migraine and Parkinson’s... right now, what we see in consensus is peaking at below $4 billion. We’ve said several times, we expect them to each peak in excess of [$5B]... I wouldn’t rule out giving another long-term update at some point.”
— Robert Michael, Chairman & CEO

Assessment: Management named the specific disconnects — migraine and Parkinson’s peaks above the Street’s <$4B, plus un-credited oncology pipeline value — rather than waving at “upside” generically. A team that quantifies where it thinks the Street is too low, while raising the current year, is the cleanest tell for a de-rated stock with room to re-rate.

The Aesthetics Cycle — Why Resilience Failed This Time

An end-of-call question pressed the apparent contradiction between AbbVie’s historical claim that aesthetics is recession-resilient and the multi-year weakness of this cycle. Management conceded the difference candidly — this was a longer inflationary consumer-pressure cycle than prior recessions — while noting markets are now stabilizing.

Q: “During periods of past economic uncertainty, AbbVie has observed and stated that aesthetics businesses were fairly resilient. But this time, it seems to be different... is my recollection correct? And if so, why is it different this time?”
— Steve Scala, TD Cowen

A: “You remember correct... in this case, we’ve seen this more lingering inflationary dynamic that we haven’t seen for 40 years. I think we’re seeing relative stability in the markets now... low single-digit growth for toxins, still decline for fillers.”
— Jeffrey Stewart, Chief Commercial Officer

Assessment: The candor is what makes the +5.1% print believable. Management is explicitly not calling a category boom — it is calling stabilization with the franchise back to growth. That is exactly the “trough confirmed, recovery un-promised” read we needed to flip the aesthetics trigger.

Skyrizi Pricing and Loss-of-Exclusivity Runway

A modeling-focused exchange flagged that Q1 Skyrizi net pricing looked flat — better than the low-single-digit erosion guided — and asked about the LOE runway. Management clarified the flatness was a year-over-year comparison gating issue (with full-year pricing still low-single-digit) and walked through the layered IP protecting Skyrizi well into the 2030s.

Q: “When I look at the 1Q Skyrizi sales versus the IQVIA scripts, it looks like net pricing is flat... can you clarify if there were any one-off items? ...And what’s your confidence in extending Skyrizi’s LOE?”
— Analyst, RBC Capital Markets

A: “The price was flat in the quarter, relatively flat. It was just a comparison year-to-year... we do continue to expect low single digit pricing for the full year... regulatory data protection for Skyrizi does not expire until 2031. So we do not expect to see biosimilar application filings until the end of this decade.”
— Scott Reents, CFO, and Robert Michael, CEO

Assessment: Both the near-term (pricing) and long-term (LOE) concerns were answered with specifics, not reassurance. A 2031 data-protection floor plus layered mid-2030s patents materially de-risks the single largest asset’s tail — the kind of durability that supports paying a quality multiple, which the de-rated price is no longer asking.

Business Development Posture — Aggression From Strength

With sector M&A active in the $5–10B range, a question probed whether AbbVie needs to be more aggressive. The CEO positioned BD as opportunistic-from-strength: focused on neuroscience, oncology, and obesity, open to early-, late-, or on-market assets, but explicitly not needed to hit top-tier growth this decade.

Q: “It’s been a very active year so far across the space, seeing companies lean in really at that kind of $5 billion to $10 billion deal size... do you see a need here to maybe be more aggressive and also push into other areas quicker than what you’re currently doing?”
— Terence Flynn, Morgan Stanley

A: “We have an on-market portfolio and an emerging pipeline that gives us a clear line of sight to very strong growth into 2030. So we are operating from a position of strength and we have ample financial capacity... while we don’t need BD to deliver top-tier growth this decade, we’re not opposed to near-term revenue drivers that are differentiated.”
— Robert Michael, Chairman & CEO

Assessment: BD-from-strength (rather than the BD-from-necessity of the pre-Humira-LOE era) is the healthier posture and keeps the recurring IPR&D charges a feature of optionality rather than a survival tax. It also caps the risk of a value-destructive large deal, since management is not under pressure to do one.

What They’re NOT Saying

1. No reinstated long-term product guidance — yet. The CEO repeatedly said he “wouldn’t rule out” reissuing the granular long-term Skyrizi/Rinvoq targets that were so useful through the Humira LOE, but declined to do so on this call. The reluctance is benign (the company would rather keep beating an un-stated bar), but it means the “upside to consensus” claim remains un-quantified — the market has to take it on management’s word.
2. No FY estimate for IPR&D beyond Q1. The raised guide explicitly excludes any acquired-IPR&D beyond the $0.41 already incurred. Given AbbVie’s active BD cadence, more IPR&D charges are near-certain — so the reported all-in 2026 EPS will land below the $14.49–$14.69 ex-IPR&D figure. Management is, as ever, not pre-announcing how big that bill will be.
3. No specifics on the Trenibot/short-duration toxin resubmission timeline. The U.S. CRL was characterized as manufacturing-only with no clinical asks, but management gave no resubmission date — leaving the timing of the U.S. aesthetics market-expansion catalyst open even as international launches proceed.
4. Quiet on the aesthetics filler structural question. Botox Cosmetic +17% carried the franchise; Juvederm was still down 2.9%, and management again attributed it to “category headwinds” without engaging the bear’s structural “natural-look”-shift argument for fillers specifically. The trough is confirmed at the franchise level, but the filler sub-line remains the soft spot.
5. No quantification of oncology’s 2026 trough. Management treated the Imbruvica decline as fully modeled but did not put a floor on where oncology revenue bottoms or when the ADC/bispecific pipeline begins to offset it — leaving the one declining franchise without a stated inflection date.

Market Reaction

• Pre-print setup: ABBV closed at $197.69 on April 28, 2026, the day before the before-open print. The stock entered the print down 13.5% YTD (from $228.49 at 2025 year-end), down 7.2% over the trailing 30 days, and only +2.2% over the trailing twelve months — against an S&P 500 up 4.3% YTD. At ~$198 the stock was changing hands at ~13.6x the ex-IPR&D 2026 guide midpoint, the cheapest level of our entire four-quarter coverage window, sitting in the lower third of its $177.44–$244.38 52-week closing range.
• Reaction-day session (April 29, before-open print): the stock initially gapped down ~2.9% to a $192.00 open, traded an unusually wide $190.75–$205.83 intraday range as the print and call were digested, and closed up +3.1% at $203.89 (+$6.20) on ~10.4M shares (1.5x the 7.2M 30-day average). The S&P 500 was flat (0.0%) on the session, so the move was idiosyncratic. The intraday round-trip — from −3.5% at the lows to a +3.1% close — captures sentiment turning in real time as the beat-and-raise and the aesthetics inflection were absorbed.

This is the data point that defines the quarter and the upgrade: for the first time in four quarters, ABBV rose on its print. The prior three reactions in our coverage window were −0.2%, −4.5%, and −3.8% — a stock that fell on every beat because every beat carried an asterisk (IPR&D noise, declining aesthetics, down oncology, a soft next-quarter guide). This quarter the asterisks cleared: the EPS beat was clean and operational, the guide was operationally raised, aesthetics turned positive, and two engines re-accelerated. The market — positioned bearishly after a 13.5% YTD de-rate — had nothing left to sell the news against, and a clean beat-and-raise into a de-rated, washed-out setup is exactly the configuration that produces a +3.1% reversal off the lows. The setup we described at Q4 as “coiling for a re-rate” began to release.

Street Perspective

Debate: Is the Sell-the-News Pattern Finally Broken?

Bull view: Three straight beats met sell-offs precisely because the stock was over-owned by execution skeptics demanding a clean, asterisk-free print before paying up. This quarter delivered exactly that — clean EPS beat, operational raise, aesthetics positive — and the stock’s +3.1% reversal off the intraday lows is the signature of a sentiment regime change. A de-rated quality compounder that has stopped falling on good news is the textbook entry point; you are buying a high-single/low-double-digit grower at ~14x with a ~3.4% yield as the multiple starts to normalize.

Bear view: One green day does not break a pattern. The stock still opened down 2.9% on the print before reversing, oncology is still declining, the aesthetics “recovery” is one quarter and management itself refused to call a category turn, and the reported all-in EPS will land below the ex-IPR&D guide once more BD charges hit. ~14x is no longer cheap if the out-year I&I competition the Street keeps flagging actually bites.

Our take: The bull has the stronger argument now, and the change since Q4 is decisive. At Q4 we wrote we were waiting for a single clean confirming print before upgrading; the +3.1% reaction is not the reason for the upgrade (the fundamentals are), but it is the market’s real-time confirmation that the sell-the-news regime — the thing that kept a good business from re-rating — is breaking. A stock that has stopped being punished for good results, while the results keep getting better, is the cleanest re-rate setup we cover.

Debate: How Much Is the I&I Out-Year Competition Worth?

Bull view: Skyrizi is hitting all-time-high new-patient starts during the competitive oral entry, AbbVie is building the next moat with its own combinations (the 382 combo doubled endoscopic remission), and regulatory data protection runs to 2031 with layered patents into the mid-2030s. Management sees upside to out-year consensus on both flagship assets — the competition is already in the (raised) guide.

Bear view: The I&I space will see a wave of new mechanisms late this decade, and even a best-in-class franchise eventually shares a growing market. The combination data is early-stage and years from revenue; the “upside to consensus” claim is un-quantified now that formal long-term guidance has been withdrawn.

Our take: The competition is real but the timeline is long and management is visibly out-innovating ahead of it. The 2033 composition-of-matter expiry, 2031 data-protection floor, and a credible internal-combination pipeline push the genuine cliff debate well past the horizon that matters for a 12-month rating. This is a multi-year watch item, not a 2026-2027 risk — and the current multiple already discounts a meaningful chunk of it.

Debate: Does Aesthetics Re-Rate the Whole Stock?

Bull view: Aesthetics returning to growth removes the last structural drag on the consolidated growth rate and, more importantly, removes the bear’s cleanest argument that a discretionary-consumer business is mis-housed in a pharma multiple. With the drag gone, the market can value AbbVie as four growth franchises (three double-digit, one recovering) rather than “two engines fighting two laggards” — a re-rate catalyst in itself.

Bear view: +5.1% operational on an easy comparison, carried by a single +17% toxin line on a favorable price compare, with fillers still declining and management refusing to call a category recovery, is a thin reed to re-rate a $360B company on. One quarter is not a trend.

Our take: The bull is directionally right but should not overreach. Aesthetics is not going to drive the stock by itself — at ~8% of revenue it is too small. What it does is remove a discount: a franchise that has stopped subtracting lets the high-quality immunology/neuroscience engines set the multiple. That is precisely the “laggard count halved” dynamic that supports a re-rate, and it is why this trigger mattered to us out of proportion to aesthetics’ revenue weight.

Model & Valuation Framework

Valuation framework: At the $203.89 reaction-day close, ABBV trades at approximately 14.0x the raised ex-IPR&D 2026 adjusted-EPS guide midpoint of ~$14.59 (and ~14.4x the as-reported ~$14.18 midpoint). That is a discount to the stock’s own historical forward multiple, a notable de-rate from the ~16x it carried at the $228 December peak, and a modest premium to the diversified large-cap pharma peer group (low-teens) that is more than justified by a superior growth profile (~10% revenue, ~13% clean EPS), a settled LOE, and now four growing franchises instead of two. On the clean like-for-like basis the stock is compounding EPS ~13% and trading at ~14x — a PEG near 1.1x — with a ~3.4% dividend yield underpinning the total-return math. The de-rate happened into improving fundamentals: the rare configuration where the multiple compressed while the forward base stepped up and the business got demonstrably better.

Fair-value anchor / 12-month framing: We raise our fair-value anchor to roughly ~$240 (base range ~$225–$255), up from the ~$215 we carried at Q4. The move reflects two things: a higher and confirmed earnings base (the operationally-raised ~$14.59 ex-IPR&D guide, which we now trust after the first clean print), and a higher justified multiple (~16–17x) as the sell-the-news discount unwinds and the franchise count improves from two-growing-two-declining to three-growing-one-recovering. Sell-side reaction corroborates the direction — the Street raised price targets into the print, with at least one major desk lifting its target to the high-$280s on higher Skyrizi and neuroscience estimates. From the $203.89 close, our ~$240 anchor implies roughly +18% price upside, plus the ~3.4% yield, for a ~21% total-return setup over twelve months — comfortably ahead of any reasonable S&P 500 expectation. A bull case (aesthetics keeps recovering, the multiple re-rates toward 17–18x as the discount fully unwinds, obesity optionality gets credited) supports the high-$260s/retest of the $244 prior high and beyond; a bear case (oncology drag worsens, aesthetics relapses, a 2026 BD print pressures reported EPS, multiple holds ~14x) supports the high-$190s — roughly where the stock already sat pre-print, i.e., limited additional downside. The asymmetry — ~+18% price upside to base, ~+30% to bull, versus ~−3% to bear — is what flips the rating. With the dividend, this now clears the Outperform bar against the S&P 500 that the Q4 setup fell just short of.

Thesis Scorecard Post-Earnings

We carry forward the bull and bear pillars established at our August (Q2) initiation and graded at Q3 and Q4, and re-grade each against the Q1 2026 evidence as of April 30, 2026. The two confirmations that constitute the spine of the upgrade — the aesthetics trough and the EPS-power re-acceleration — are highlighted.

Overall: The thesis is unambiguously strengthened, and for the first time the bear pillars are resolving rather than merely “watching.” All three of our standing upgrade triggers are now satisfied: (1) the aesthetics trough is confirmed (the franchise grew +5.1% op. after a year of declines); (2) the first clean 2026 print confirmed the ex-IPR&D earnings power and the guide was operationally raised; and (3) the entry-price trigger resolved favorably as the stock de-rated to ~$198/~14x into improving fundamentals. Two of the four bear pillars (full valuation, structural aesthetics decline) flipped from headwind to resolved; a third (policy) is contained; only oncology remains a genuine negative — and it is small, marginal, and self-limiting. The franchise count improved from two-growing-two-declining (Q4) to three-growing-one-recovering (Q1). The +3.1% reaction was the market confirming the inflection in real time.

Action: Upgrading to Outperform from Hold. This is the payoff of three disciplined Holds. We initiated at Hold in August, maintained through Q3, and maintained again at Q4 while explicitly flagging the setup as “one clean confirming quarter away” from an upgrade. That quarter arrived. We resisted upgrading on the anticipation of these confirmations because a quality compounder priced for execution earns the upgrade on the confirmation, not the hope — and the confirmations are now in hand across all three triggers, with the market itself validating the turn (+3.1%, the first positive print reaction of our coverage). From the $203.89 close at ~14x a raised guide with a ~3.4% yield and a ~$240 fair-value anchor, the risk/reward has flipped clearly favorable: roughly +18% price upside to base plus the dividend, against limited downside to a price the stock already sat at pre-print. The one residual risk — a still-declining oncology line — is small, bounded, and well-understood, and is not enough to outweigh two double-digit engines, a recovering aesthetics franchise, and a multiple that compressed while the business got better. We would revisit only on a genuine operational crack the platform cannot earn through (not in evidence) or a multiple that runs back to the mid-teens on a sentiment overshoot. We upgrade to Outperform.

Bottom Line: The Confirming Quarter, and the Upgrade It Earned

For three quarters we held AbbVie through good-but-complicated prints — clean beats the tape kept selling because each carried an asterisk. At Q4 we said the setup was tilting toward an upgrade and that we were, in the most literal sense, one clean confirming quarter away. Q1 2026 is that quarter. Revenue of $15.002B (+12.4%) and adjusted EPS of $2.65 both beat cleanly; the full-year guide was operationally raised $0.12 to ~$14.59 ex-IPR&D; immunology re-accelerated to +16.4% and neuroscience to +26.0%; and — the data point we had been waiting on — aesthetics returned to growth at +5.1% operationally, the first positive print in over a year. All three of our explicit upgrade triggers are satisfied at once.

And for the first time in four quarters, the market agreed in real time: the stock rose +3.1% to $203.89, reversing the −0.2% / −4.5% / −3.8% reactions that had defined the prior year. A clean beat-and-raise into a stock that had de-rated 13.5% YTD to ~14x left the bears with nothing to sell the news against, and the intraday round-trip from −3.5% to a +3.1% close is the signature of a sell-the-news regime breaking. The one remaining drag — oncology, down a marginal 0.2% reported on Imbruvica’s IRA erosion — is now the lone laggard against three growing franchises, and a small, self-limiting one at that.

We upgrade AbbVie to Outperform from Hold. The discipline of three Holds was not timidity — it was waiting for the de-rated quality compounder to confirm the inflection before paying up, and then paying up at ~14x rather than ~16x. From here, four growing franchises (three double-digit, one recovering), an operationally raised and now-confirmed earnings base, a ~3.4% yield, fresh obesity optionality, and a multiple that compressed while the business improved combine into a risk/reward that clears the Outperform bar against the S&P 500. The good news is, at last, no longer fully in the price — and the tape has started to notice.